Health News

Adcetris May Increase Risk of Lung Toxicity in Younger Hodgkin's Lymphoma Patients, Study Suggests

 1 year ago       183 Views

Adcetris (brentuximab vedotin) treatment may increase the chances of lung toxicity in children and young adults with relapsed or refractory Hodgkin’s lymphoma, a small retrospective study suggests.

Adcetris, developed by Takeda Oncology in collaboration with Seattle Genetics, is an immunotherapy approved for classical Hodgkin’s lymphoma and systemic anaplastic large cell lymphoma.

As a single treatment, Adcetris is associated with positive outcomes and low toxicity to the lungs.

The safety profile of a combination therapy is an important consideration when choosing the best treatment approach, but little is known about lung-related adverse events in children and young adults with Hodgkin’s lymphoma who are on Adcetris.

To address this, researchers at the University of Colorado analyzed the pulmonary toxicity in 19 Hodgkin’s lymphoma patients, at a median age of 14.5 years, who received Adcetris alone or with other agents known to cause lung toxicity — bleomycin, gemcitabine, radiation, or carmustine.

Of the 19 patients, seven (36.8%) received Adcetris treatment, six as a stand-alone therapy and one in combination with gemcitabine.

Exposure to other medications did not influence the rate of lung infections.

Overall, Hodgkin’s lymphoma patients who received Adcetris were four times more likely to experience lung toxicity than those who did not receive this medicine.

They also suggest that larger, multicenter trials may be needed to further evaluate this risk in these patients.

Print This Page

Author: @DailyCupofYoga


Join the community!

You must be a member of healtheo360 in order to view this group

Register with Email Address

Already a member? Click here to login

healtheo360 believes strongly in user privacy.